Beta Bionics, Inc.

Beta Bionics, Inc.

NNASDAQ:BBNX
15.21
USD
-1.21
(-7.37%)
-1.85EPS
1.03BMarket Cap
Mar 30Next Earn
Beta Bionics, Inc.
NASDAQ:BBNX
(Nasdaq Stock Market)

Recent

price

15.21

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
USD
0.01
0.39
1.52
2.47
2.83
Revenue per Share
-2.12
-1.45
-1.28
-1.81
-1.85
Basic EPS, GAAP
-2
-1.08
-1.21
-1.39
-1.47
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
-3.97
-4.74
-5.72
6.48
7.38
Book Value per Share
-3.97
-4.74
-5.72
6.48
7.38
Tangible Book Value per Share
30
30
43
41
45
Basic Weighted Avg Shares
- -
12
65
100
127
Sales/Revenue/Turnover
-36,784.36
-298.87
-69.48
-71.5
-72.75
Operating Margin (%)
2
2
2
3
4
Depreciation Expense
-65
-44
-55
-73
-83
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-36,173.74
-367.64
-84.08
-73.02
-65.31
Profit Margin (%)
20
93
112
237
260
Working Capital
3
3
6
5
5
LT Debt
-170
-203
-245
288
401
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-23.88
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
2
1
LT Borrowings
- -
- -
- -
LT Finance Leases
5
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
45
54
Market Capitalization
447
705
1,032

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
248
231
293
Cash, Cash Equivalents & STI
200
180
240
Accounts Receivable, Net
16
18
21
Inventories
24
24
23
Total Current Liabilities
23
26
33
Payables & Accruals
8
10
13
ST Debt
2
2
1
Deferred Revenue
2
2
2

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-217.22%
Free Cash Flow
- -
- -
8.81%
Net Income, GAAP
- -
- -
33.68%
Sales/Revenue/Turnover
- -
- -
53.94%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13
15
17
20
65
2025
18
23
27
32
100
2026
28
32
36
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.41
-0.34
-0.23
-0.42
-1.28
2025
-0.93
-0.39
-0.33
-0.3
-1.81
2026
-0.49
-0.53
-0.52
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Beta Bionics, Inc. (NASDAQ:BBNX) develops and commercializes automated insulin delivery systems for people with insulin-dependent diabetes. The company offers the iLet Bionic Pancreas, an FDA-cleared autonomous insulin delivery device for adults and children aged six years and older that integrates with Dexcom or FreeStyle Libre 3 Plus continuous glucose monitors to automatically compute and deliver insulin doses without requiring carb counting, correction factors, or preset basal rates; a Color iLet variant featuring a color screen and enhanced alerts; and related monthly supplies. Beta Bionics develops additional pipeline products including a tubeless Patch Pump that adheres directly to the skin, a Bihormonal iLet combining automated insulin and glucagon delivery, and an iLet configuration for insulin-dependent type 2 diabetes. Founded in 2015 and headquartered in Irvine, California, with operations in Massachusetts, the company targets people with diabetes globally, emphasizing simplified management through adaptive algorithms. Beta Bionics maintains strategic partnerships, including a collaboration and license agreement with Xeris Pharmaceuticals, Inc. for a pump-compatible glucagon formulation and a development agreement with Abbott Diabetes Care Inc. for automated insulin delivery systems. In November 2024, Beta Bionics closed a $60 million Series E funding round led by Wellington Management with participation from existing investors including Eventide Asset Management and RTW Investments to support iLet commercialization, pipeline advancement, and manufacturing expansion. The company completed its initial public offering on NASDAQ in January 2025 and reported full-year 2024 revenue of $65.1 million, reflecting 443% year-over-year growth and an install base exceeding 15,000 users. Beta Bionics continues to pursue pharmacy reimbursement for the iLet system while advancing bihormonal and patch pump initiatives.

Company News

  • Beta Bio: 3 Key Takeaways for Long-Term Investors

  • INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX

  • BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

  • BBNX Deadline Today: Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights

  • SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX

  • CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

  • Beta Bionics, Inc. (NASDAQ:BBNX) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact Portnoy Law Firm

  • Beta Bionics Announces Participation at Upcoming Investor Conferences

  • BBNX FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

  • BBNX FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

  • BBNX FINAL DEADLINE ALERT: Beta Bionics Investors with Losses Encouraged to Contact Hagens Berman Before Nov. 3rd Deadline in Securities Class Action

  • INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

  • DEADLINE ALERT for DICK'S Sporting Goods, Inc. (DKS), Beta Bionics, Inc. (BBNX), Better Home & Finance Holding Company (BETR), and Coastal Financial Corporation (CCB): The Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

  • Deadline Alert: Beta Bionics, Inc. Investors Have Until November 3, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

  • Kaplan Fox Reminds Beta Bionics, Inc. (NASDAQ: BBNX) Investors of an Approaching Securities Class Action Deadline on November 3, 2026

  • DEADLINE ALERT for DICK'S Sporting Goods, Inc. (DKS), Beta Bionics, Inc. (BBNX), FuelCell Energy, Inc. (FCEL), and Lincoln Educational Services Corp. (LINC),: The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions

  • Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNX

  • BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit

  • DEADLINE TOMORROW: Berger Montague Advises Beta Bionics, Inc. (BBNX) Investors to Inquire About a Securities Fraud Class Action by November 3, 2026

  • Kaplan Fox Reminds Investors of Beta Bionics, Inc. (BBNX) of the Deadline to Seek Lead Plaintiff Status on November 3, 2026